U.S., Nov. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07228195) titled 'SGLT2i Therapy in Islet Transplantation (SIT)' on Oct. 17.
Brief Summary: This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who have partial islet function.
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition:
Partial Islet Function
TPIAT
Diabetes
Intervention:
DRUG: Empagliflozin 25 MG Oral Tablet
Empagliflozin, which is sold under the name of Jardiance, is FDA approved for patients 10 years of age and older to improve glycemic control in typ...